<DOC>
	<DOCNO>NCT01158183</DOCNO>
	<brief_summary>A Web base real world observational study Relapsing-Remitting Multiple Sclerosis ( RRMS ) population capture outcome report patient physician 12 month initiate resume Betaseron .</brief_summary>
	<brief_title>Real-World Betaseron Health Economic Outcomes Study Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Provides write informed consent participate study At least 18 65 year old Documented clinical diagnosis relapse form multiple sclerosis confirm clinically isolate syndrome ( CIS ) Initiating Betaseron therapy , resume Betaseron use least three month Willing able provide valid email address use duration study Willing able complete study questionnaire via Internet Has reliable Internet access duration study Completes baseline patient questionnaire Kurtzke Expanded Disability Status Scale ( EDSS ) score great 6.0 Cognitive dysfunction , Investigator 's judgment , raise doubt study participant 's ability provide inform consent accurately complete monthly patient questionnaire Any use Betaseron within three month prior study entry Inability read , write , speak English language Illness disease multiple sclerosis Investigator believe likely cause patient 's death incapacity within twelve month Any severe , uncontrolled illness condition Investigator believe could dominate patient 's quality life Coexistent autoimmune disease rheumatoid arthritis , lupus , psoriasis likely exacerbate treatment Interferon Current use immunosuppressive medication Previous participation multiple sclerosis ( MS ) clinical trial within three month prior study entry Previous use monoclonal antibody treat MS within three month prior study entry Current use secondary treatment multiple sclerosis episodic use steroid relapse exacerbation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Outcomes</keyword>
	<keyword>real world web tool</keyword>
	<keyword>electronic data capture</keyword>
</DOC>